SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
This Connecticut firm has alliances with Pfizer and Schering on technology leads in treating obesity and psychiatric illnesses. One of the few biotechs with a reasonable P/E of 16. Also perceived to have excellent, proprietary science in combinatorial chemistry (from which it got those ob/psych leads - more should come.)

Given the recent softness in biotech overall, it appears to be an excellent buy. Does anyone have additional insights, information or opinions?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
523A sad end to a long history: Neurogen Corporation Announces Agreement for Sale mopgcw-12/24/2008
522Do they at least get to keep the down deposit? :) Neurogen Corporation Announrkrw-12/2/2008
521Neurogen Corporation Announces Agreements for Sale of Non-Core Assets for Combinmopgcw-11/15/2008
520Neurogen Corporation Announces Third Quarter 2008 Financial Results and Updates mopgcw-11/8/2008
519Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and mopgcw-10/14/2008
518Yes, though burn has been addressed. Eventual dilution, as they run through remJohn Metcalf-9/3/2008
517Problem I see is they continue to pour money down the drain with their gaba sleerkrw-9/3/2008
516Neurogen is close to trading below furniture value. M/C has fallen below net woJohn Metcalf-9/3/2008
515Maybe a good contrarian signal :)rkrw-9/2/2008
514Q2 transcript: Only one question. seems like no one is following this one anmopgcw-9/2/2008
513Another example of how special release formulations are not so easy. That also kenhott-7/15/2008
512Last I heard, NGD-8243 is still being pursued by merck for cough, and NGD-9611 wmopgcw-7/15/2008
511cs: Neurogen Corp (NRGN) Neutral [V] Y. Katherine Xu CP: US$ 1.01 TP: US$ 3 CAP:mopgcw-7/15/2008
510Yes, it's sad. What's left besides Aplindore? Is the Vanilloid ReceptoJohn Metcalf-7/14/2008
509NRGN pulls a Panacos with Adipiplon: >>Neurogen Announces Suspension of Ituck-7/14/2008
508cc transcript: seekingalpha.commopgcw-6/1/2008
507Neurogen Corporation Announces First Quarter 2008 Financial Results Thursday Maymopgcw-5/8/2008
506Neurogen Corporation Announces Executive Appointments Thursday April 24, 4:15 pmmopgcw-4/25/2008
505NRGN indefinitely delays Schizophrenia trial, lays off about 50% of its survivinpgo-neil-4/9/2008
504Neurogen Corporation Announces 2007 Financial Results Monday March 17, 6:00 am Emopgcw-3/17/2008
503Neurogen Announces R&D Update Friday February 8, 6:00 am ET Conference calmopgcw-2/8/2008
502CORRECTING and REPLACING Neurogen Restructures to Focus Resources on Advancing Cmopgcw-2/7/2008
501And there's the cash issue: They ended 3Q07 with approx $57M in cash, and reidos-1/8/2008
500since i have a loss on paper, will ride it out for the year and see what is whatmopgcw-1/8/2008
499agree with Tuck..... all of this bad news has been front-run. not cool. scaram(o)uche-1/8/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News